One- and Twelve-Month Safety and Efficacy Outcomes of Patients Undergoing Edge-to-Edge Percutaneous Mitral Valve Repair (from the GRASP Registry)

• Published in: The American journal of cardiology Vol. 111; no. 10; pp. 1482 - 1487
• Main Authors: Grasso, Carmelo, MD, Capodanno, Davide, MD, PhD, Scandura, Salvatore, MD, Cannata, Stefano, MD, Immè, Sebastiano, MD, Mangiafico, Sarah, MD, Pistritto, Anna, MD, Ministeri, Margherita, MD, Barbanti, Marco, MD, Caggegi, Anna, MD, Chiarandà, Marta, MD, Dipasqua, Fabio, MD, Giaquinta, Sandra, MD, Occhipinti, Michele, MD, Ussia, Gianpaolo, MD, Tamburino, Corrado, MD, PhD
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 15.05.2013; Elsevier Limited
• Subjects: Aged; Cardiac Catheterization; Cardiology; Cardiovascular; Cardiovascular disease; Coronary vessels; Echocardiography; Female; Follow-Up Studies; Heart attacks; Heart Valve Prosthesis Implantation - methods; Humans; Italy - epidemiology; Male; Mitral Valve - surgery; Mitral Valve Insufficiency - diagnosis; Mitral Valve Insufficiency - mortality; Mitral Valve Insufficiency - surgery; Mortality; Prospective Studies; Prosthesis Design; Safety; Severity of Illness Index; Survival Rate - trends; Time Factors; Treatment Outcome; Italy; Illinois; Europe
• ISSN: 0002-9149; 1879-1913
• DOI: 10.1016/j.amjcard.2013.01.300

The aim of this study was to report on the 30-day and 1-year outcomes of percutaneous mitral valve repair with the MitraClip technique in patients with grade ≥3+ mitral regurgitation (MR) at high risk for conventional surgical therapy enrolled in the prospective Getting Reduction of Mitral Insufficiency by Percutaneous Clip Implantation (GRASP) registry. Acute device success was defined as residual MR ≤2+ after clip implantation. The primary safety end point was the rate of major adverse events at 30 days. The primary efficacy end point was freedom from death, surgery for mitral valve dysfunction, or grade ≥3+ MR at 30 days and 1 year. A total of 117 patients were treated. Eighty-nine patients (76%) presented with functional MR and 28 patients (24%) with organic MR. Acute device success was observed in all patients. Device implantation time significantly diminished with experience and varied significantly between cases with 1 versus ≥2 clips. No procedural mortality was recorded. Major adverse events occurred in 4 patients at 30 days (4.3%). Deterioration to MR ≥3+ was recorded in 25% of patients with degenerative MR and 7% of those with functional MR at 1 year. No surgery for mitral valve dysfunction occurred within 1 year. Freedom from death, surgery for mitral valve dysfunction, or grade ≥3+ MR was 96.4% and 75.8% at 30 days and 1 year, respectively. No significant differences were noted in the primary efficacy end point between patients with degenerative MR and those with functional MR. In conclusion, percutaneous mitral valve repair with the MitraClip technique was shown to be safe and reasonably effective in 117 patients from a real-world setting.